Answers are grounded in this paper and cite their sources.
Stiff-person syndrome (SPS) is a neuroimmunologic disorder characterized by painful spasms and muscle rigidity attributed to impaired inhibitory γ-aminobutyric acid (GABA) descending pathways.1 The immunopathogenesis remains unknown and the pathogenic significance of antibodies against glutamic acid decarboxylase (GAD) is controversial. Herein, we report 4 cases of anti-GAD65-positive patients with SPS (table e-1 at [Neurology.org/nn][1]) who had significant worsening of symptoms and disability with the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine (table e-2). While causation cannot be proven, these observations suggest the importance of investigating the relationship between SNRI use and SPS clinical exacerbations (figure, A). [1]: /lookup/doi/10.1212/NXI.0000000000000281
No takes yet. Share an insight, caveat, or question.
Benavides et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: